Pain Therapeutics (NASDAQ:PTIE) issued its quarterly earnings results on Monday. The biopharmaceutical company reported ($0.11) EPS for the quarter, beating analysts’ consensus estimates of ($0.61) by $0.50, MarketWatch Earnings reports.
PTIE traded down $0.05 on Tuesday, reaching $1.12. The company’s stock had a trading volume of 752 shares, compared to its average volume of 5,851,778. The company has a market capitalization of $8.52 million, a P/E ratio of -0.62 and a beta of 2.62. Pain Therapeutics has a 1 year low of $0.81 and a 1 year high of $12.80.
In other Pain Therapeutics news, major shareholder Armistice Capital, Llc sold 1,200,000 shares of the stock in a transaction that occurred on Thursday, August 16th. The stock was sold at an average price of $1.02, for a total transaction of $1,224,000.00. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, major shareholder Armistice Capital Master Fund sold 512,660 shares of the stock in a transaction that occurred on Wednesday, October 3rd. The stock was sold at an average price of $1.31, for a total value of $671,584.60. The disclosure for this sale can be found here. Insiders sold 2,968,660 shares of company stock valued at $3,176,705 in the last three months. 31.40% of the stock is currently owned by company insiders.
Pain Therapeutics, Inc develops drugs for nervous system disorders in the United States. The company's lead drug candidate is REMOXY, a proprietary abuse-deterrent oral formulation of oxycodone to treat severe chronic pain. It is also developing FENROCK, a proprietary abuse-deterrent transdermal pain patch for pain relief; PTI-125, a small molecule drug candidate to treat Alzheimer's disease; and PTI-125DX, a blood-based diagnostic/biomarker to detect Alzheimer's disease.
Receive News & Ratings for Pain Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pain Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.